Samsung Biologics Co.,Ltd. agreed to Spin-Off CDMO business of Samsung Biologics on May 22, 2025. The Spin off ratio is 0.3496087. Transaction is subject to approval from Samsung Biologics 's shareholders. The transaction is expected to complete on October 01, 2025. As per the announcement dated August 22, 2025, The record date of the transaction is set as October 31, 2025 and the transaction is expected to close on November 1, 2025.

Samsung Biologics Co.,Ltd. completed the Spin-Off of CDMO business of Samsung Biologics on November 1, 2025. Samsung Epis Holdings to be listed on Korea Exchange (KRX) on November 24, 2025. The transaction received regulatory approval in September, and secured shareholder consent at the Extraordinary General Meeting held on October 17, 2025. Samsung Epis Holdings to focus on exploring next-generation growth drivers and optimizing business strategies for its subsidiaries ?Samsung Bioepis and a new company under Samsung Epis Holdings. Samsung Bioepis will continue to operate its biosimilar business as a 100% owned subsidiary of Samsung Epis Holdings while the new subsidiary company under Samsung Epis Holdings will focus on developing next-generation biotechnology platforms. The transaction received regulatory approval in September, and secured shareholder consent at the Extraordinary General Meeting held on October 17, 2025.